Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Pinacidil

Pinacidil (P-1134) is a potent activator of ATP-sensitive potassium channel. Pinacidil is an antihypertensive agent hyperpolarizes vascular smooth muscle by opening K+ channels. Pinacidil enhances K+-efflux in smooth muscle. Pinacidil has vasorelaxant properties. Pinacidil is able to inhibit spontaneous tone and of reducing agonist induced contractions. Pinacidil can be studied in research area such as cardiovascular diseases[1][2].

Product Specifications

CAS Number

[60560-33-0]

Product Name Alternative

P-1134

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/pinacidil.html

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C(C)(C)C)N/C(NC1=CC=NC=C1)=N\C#N

Molecular Formula

C13H19N5

Molecular Weight

245.32

Precautions

H315, H319, H320

References & Citations

[1]Hamilton TC, et al., Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol. 1989;20 (1) :1-9. |[2]Jung-Ae Kim, et al., Activation of Na+, K+, Cl−-Cotransport Mediates Intracellular Ca2+ Increase and Apoptosis Induced by Pinacidil in HepG2 Human Hepatoblastoma Cells, Biochemical and Biophysical Research Communications, Volume 281, Issue 2, 2001, Pages 511-519, ISSN 0006-291X, |[3]Weston, A.H., et al., In Vitro Studies on the Mode of Action of Pinacidil. Drugs 36 (Suppl 7), 10–28 (1988) .|[4]Ko Zushida, et al ., Effect of diabetes on pinacidil-induced antinociception in mice, European Journal of Pharmacology, Volume 453, Issues 2–3, 2002, Pages 209-215, ISSN 0014-2999.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Patent. US20240299405A1.|Sci Rep. 2024 Sep 30;14 (1) :22695.|Bone Res. 2022 Mar 8;10 (1) :25.|Dev Cell. 2022 Jun 6;57 (11) :1383-1399.e7.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Human CYB561D1 (NM_182580) AAV Particle
RC210795A1V 250 µL

Human CYB561D1 (NM_182580) AAV Particle

Ask
View Details
PCID2 (FITC)
571625-01 50 µg

PCID2 (FITC)

Ask
View Details
PCID2 (FITC)
571625-02 100 µg

PCID2 (FITC)

Ask
View Details
Anti-Matrix Metalloproteinase 10 (MMP10) Monoclonal antibody
FY-AB34460-01 1 mL

Anti-Matrix Metalloproteinase 10 (MMP10) Monoclonal antibody

Ask
View Details
Anti-Matrix Metalloproteinase 10 (MMP10) Monoclonal antibody
FY-AB34460-02 100 µL

Anti-Matrix Metalloproteinase 10 (MMP10) Monoclonal antibody

Ask
View Details
Anti-Matrix Metalloproteinase 10 (MMP10) Monoclonal antibody
FY-AB34460-03 200 µL

Anti-Matrix Metalloproteinase 10 (MMP10) Monoclonal antibody

Ask
View Details